

Author Index

- Abi-Rached, Laurent, 491
 Adriouch, Sahil, 186
 Ahluwalia, Neil, 691
 Aikawa, Masanori, 691
 Alam, Rafeul, 682
 Aldinucci, Alessandra, 305
 Allen, Paul M., 3
 Allen, Stephanie D., 472
 Allende, Miguel L., 357
 Altmayr, Felicitas, 607
 Alves, Nuno L., 221
 Anderson, D. Eric, 26
 Anderson, Kathleen M., 141
 Anderson, Thomas J. T., 691
 Apelt, Jenny, 365
 Armstrong, Allison, 266
 Ashare, Alix, 505
 Atzberger, Ann, 89
 Auricchio, Salvatore, 372
 Au-Yeung, Byron B., 111
- Badovinac, Vladimir P., 53
 Badwey, John A., 647
 Bakshi, Chandra Shekhar, 532
 Balboa, María A., 631
 Balkow, Sandra, 365
 Ballerini, Clara, 305
 Balsinde, Jesús, 631
 Bartsch, Sebastian, 295
 Basaraba, Randall J., 522
 Bateman, Henry R., 665
 Bäumel, Monika, 154
 Befus, A. Dean, 256
 Beigier-Bompadre, Macarena, 673
 Beissert, Stefan, 365
 Berndt, Uta, 295
 Bès, Cédric, 409
 Bettelli, Estelle, 179
 Betten, Åsa, 21
 Biagioli, Tiziana, 305
 Blom, Anna M., 540
 Boboila, Cristian, 195
 Bolland, Silvia, 95
 Bommarius, Bettina, 566
 Bonneau, Robert H., 322
 Bordignon, Claudio, 357
 Borgognoni, Lorenzo, 305
 Borrow, Persephone, 597
 Bowness, Paul, 89, 597
 Boyd, Rochelle, 172
 Braciale, Thomas J., 391
 Brahmachari, Saurav, 275
 Branstetter, Daniel, 266
 Brittingham, Katherine C., 313
 Brown, Kevin K., 682
 Buckley, Christopher D., 89
 Bumgardner, Ginny L., 80
 Bushnell, Timothy P., 247
 Bussiere, Jeanine, 266
 Bzik, David J., 590
- Cahalon, Liora, 41
 Cameron, Lisa, 256
 Canté-Barrett, Kirsten, 103
 Carbone, Ennio, 372
 Cariappa, Annaiah, 195
 Carter, Nicole, 172
 Casas, Javier, 631
 Catalan Pellet, Antonio C., 673
 Cérutti, Martine, 409
 Cha, Edward N., 463
 Chan, Antoni, 89
- Chardès, Thierry, 409
 Chen, Xin, 154
 Chentouf, Myriam, 409
 Cheong, JaeHun, 26
 Chiarugi, Alberto, 305
 Cho, Hyun Kook, 26
 Cipriani, Giulia, 305
 Cohen, Irun R., 41
 Cohen-Sfady, Michal, 41
 Conforti, Laura, 346
 Conlon, Christopher, 597
 Cornelius, Janet G., 382
 Cosgrove, Gregory P., 682
 Cotelli, Franco, 357
 Court, Felipe A., 357
 Cowan, Laine, 266
 Coyle, Anthony, 179
 Crabtree, Gerald R., 103
 Crispe, Ian N., 201
 Cruz, Anna R., 691
 Cush, Stephanie S., 141
- Danese, Silvio, 295
 da Rocha Dias, Silvy, 400
 David-Fung, Elizabeth-Sharon, 421
 Dechant, Claudia, 337
 De Giulio, Beatrice, 372
 de Saint-Mezard, Sophie, 372
 di Gleria, Kati, 597
 Dignass, Axel U., 295
 Ding, Yong, 647
 Dodds, Alistair W., 455
 Doherty, Peter C., 64
 Dohi, Makoto, 284
 Dong, Tao, 597
 Dorrell, Lucy, 597
 Dougall, William C., 266
 Duffy, Patrick E., 557
 Duncan, Heather J., 346
 Duta, Florentina, 256
 Dye, John R., 229
 Dziema, Heather L., 80
- El Kebir, Driss, 616
 Enver, Tariq, 89
- Filep, János G., 616
 Filer, Andrew D., 89
 Filipovich, Alexandra H., 346
 Flaño, Emilio, 141
 Forni, Guido, 472
 Fossati, Silvia, 305
 Fourcade, Mariano G., 673
 Fowell, Deborah J., 111
 Frank, Carola, 337
 Freeman, Michael L., 322
 Fried, Michal, 557
 Fujimoto, Manabu, 698
 Fujimoto, Yukari, 514
 Fujita, Tomoyuki, 698
 Fukase, Koichi, 514
- Gais, Petra, 607
 Gao, Jue-hua, 382
 Garrett, Joan T., 472
 Gerlini, Gianni, 305
 Gerszten, Robert E., 691
 Ghannam, Soufiane, 409
 Gianfrani, Carmen, 372
 Giannandrea, Matthew, 201
 Gibbings, Derrick, 256
 Gigley, Jason, 590
- Girija, Umakhanth Venkatraman, 455
 Glennie, Martin, 337
 Golden, Jacqueline M., 532
 Golenbock, Douglas, 162
 Gomez, Greg, 665
 Good, Kim L., 13
 Goonetilleke, Nilu, 597
 Gorgun, Cem Z., 313
 Gorham, James D., 71
 Gorska, Magdalena M., 682
 Grabbe, Stephan, 365
 Greve, Bernhard, 179
 Gruenthal, Michael, 313
 Guan, Hongbing, 590
 Guethlein, Lisbeth A., 491
 Guo, Benchang, 229
- Haag, Friedrich, 186
 Hall, Bruce M., 172
 Hamdi, Nada, 179
 Hämmerle, Marcus, 295
 Hanke, Tomáš, 597
 Harris, Kathleen E., 578
 Harton, Marisa, 522
 Harty, John T., 53
 Harzenetter, Marit D., 607
 Hasegawa, Minoru, 698
 Hasturk, Hatice, 647
 Hellstrand, Kristoffer, 21
 Henao-Tamayo, Marcela, 522
 Hendricks, Robert L., 322
 Hermesen, Cornelius C., 162
 Herrmann, Martin, 337
 Hisamori, Shigeo, 708
 Hodgkinson, Suzanne J., 172
 Holt, Patrick G., 132
 Holzmann, Bernhard, 607
 Hong, Choongman, 329
 Hong, Deng-Li, 89
 Horikawa, Mayuka, 698
 Horne, Phillip H., 80
 Horner, Heike, 337
 Hotamisligil, Gökhan S., 313
 Howard, O. M. Zack, 154
 Huang, Ching-Yu, 449
 Hubert, Sandra, 186
 Hunninghake, Gary W., 505
 Hurrelbrink, Robert J., 132
 Hwang, Il-Young, 439
- Inohara, Naohiro, 514
 Iskandar, Monica, 211
 Isturiz, Martín A., 673
 Iype, Tessy, 483
- Jabri, Bana, 372
 Jacobs, Liesbeth, 162
 Jameson, Stephen C., 120
 Jang, Moon Kyoo, 26
 Jansen, Trees, 162
 Jarva, Hanna, 540
 Jayashankar, Kartika, 80
 Jenkins, Misty R., 64
 Jones, Audra L., 472
 Jones, Jon, 266
 Jones, Taneishia, 45
 József, Levente, 616
- Kadokawa, Yoshio, 708
 Kalman, Daniel, 566
 Kanneganti, Thirumala-Devi, 514
 Kano, Mitsunobu R., 284

- Kant, Shashi K., 346
 Kantarci, Alpdogan, 647
 Kaumaya, Pravin T. P., 472
 Kawasuji, Ayako, 698
 Kedzierska, Katherine, 64
 Kehrl, John H., 439
 Kennedy, Bryan, 266
 Kepley, Christopher L., 665
 Khan, Imtiaz A., 590
 Khreiss, Tarek, 616
 Killingsworth, Murray C., 172
 Kim, Hyuna, 382
 Kim, Yun-Gi, 514
 Kirimanjeswara, Girish S., 532
 Klein, Ingo, 201
 Klinman, Dennis M., 329
 Koch-Nolte, Friedrich, 186
 Koester, Mitchel A., 80
 Kollnberger, Simon, 89
 Kong, Hee Jeong, 26
 Kosaki, Naoto, 639
 Kouro, Taku, 284
 Krishnan, Lakshmi, 211
 Kristo, Fjoralba, 691
 Kubo, Hajime, 708
 Kuchroo, Vijay K., 179

 Laborde, Evangelina A., 673
 Lachowitz, Jeff, 557
 Laing, Ingrid A., 132
 Lawrence, B. Paige, 247
 Lebeis, Sarah L., 566
 Lee, Carolyn, 463
 Lee, Chang Hoon, 26
 Lefrançois, Leo, 36
 Legge, Kevin L., 391
 Lenk, Robert, 665
 Leppert, Brian J., 548
 Le Souef, Peter, 132
 Leung, Wai-Hang, 95
 Lider, Ofer, 41
 Lin, Alexander Y., 691
 Liu, Haoyuan, 195
 Liu, Qiaohong, 313
 Liu, Yawei, 313
 Londei, Marco, 372
 Lorenz, Ulrike, 483
 Loser, Karin, 365
 Lunsford, Keri E., 80
 Luster, Andrew D., 691

 Ma, Zhong, 483
 Magnusson, Mattias, 31
 Maiuri, Luigi, 372
 Malabanan, Alan, 647
 Männel, Daniela N., 154
 Mansfield, John M., 548
 Marcet-Palacios, Marcelo, 256
 Marzo, Amanda L., 36
 Massacesi, Luca, 305
 Matsumoto, Hideo, 639
 Matsushita, Takashi, 698
 Matsushita, Yukiyo, 698
 Maurano, Francesco, 372
 Mayers, Irvin, 256
 Mazzarella, Giuseppe, 372
 McCall, Matthew B. B., 162
 McMichael, Andrew, 89, 597
 McPhie, Peter, 45
 Metzger, Dennis W., 532
 Miller, Robert E., 266
 Mishima, Michiaki, 708
 Miyamoto, Takeshi, 639
 Miyazaki, Jun-ichi, 284
 Miyazono, Kohei, 284
 Mohaupt, Mariette, 365
 Molina, Carlos A., 607
 Molleran Lee, Susan, 346

 Mongey, Anne Barbara, 346
 Monick, Martha M., 505
 Moore, Jonathan E., 421
 Moran, Stewart T., 195
 Moretto, Magali, 590
 Moroni, Flavio, 305
 Morris, John C., 472
 Morrison, John M., 505
 Morse, Herbert C., III, 26
 Muehlenbachs, Atis, 557
 Muir, Beth, 195
 Munoz, Samira, 256
 Mutabingwa, Theonest K., 557
 Mykytczuk, Oksana L., 211

 Nakagome, Kazuyuki, 284
 Nakano, Takashi, 708
 Nash, John H. E., 211
 Neff-LaFord, Haley, 247
 Netea, Mihai G., 162
 Neumeier, Lisa, 346
 Ngampasutadol, Jutamas, 540
 Nguyen, Cuong Q., 382
 Nicolaou, Stella A., 346
 Niki, Yasuo, 639
 Noble, Matthew, 505
 Norcross, Michael A., 45
 Norton, Sarah K., 665
 Novotny, Alexander R., 607
 Núñez, Gabriel, 514
 Nymon, Amanda B., 505

 Ogawa, Fumihide, 698
 Okunishi, Katsuhide, 284
 Older Aguilar, Anastazia M., 491
 Ondondo, Beatrice, 597
 Oppenheim, Joost J., 154
 Ordway, Diane, 522
 Orme, Ian M., 522
 Oshima, Robert G., 472
 Osuchowski, Marcin F., 623
 Ozato, Keiko, 26

 Pahan, Kalipada, 275
 Paizis, Kathy, 172
 Palanisamy, Gopinath, 522
 Palvanov, Arkadiy, 229
 Pan, Wanling, 616
 Pareja, Eduardo, 31
 Parham, Peter, 491
 Park, Christopher Y., 463
 Park, Chung, 439
 Park, Jong-Hwan, 514
 Parkos, Charles A., 566
 Paulnock, Donna M., 548
 Pechberty, Severine, 186
 Peck, Ammon B., 382
 Petasis, Nicos A., 616
 Petrenko, Lev, 329
 Pevsner-Fischer, Meirav, 41
 Philipsen, Lars, 295
 Phillips, Gary, 472
 Pillai, Shiv, 195
 Pimpinelli, Nicola, 305
 Pistocchi, Anna, 357
 Polakos, Noelle K., 201
 Polumuri, Swamy Kumar, 236
 Power, David A., 172
 Powers, Linda S., 505
 Prêle, Cecilia M., 132
 Pruitt, Ivy E., 691
 Puttagunta, Lakshmi, 256

 Radomski, Marek, 256
 Rajewsky, Klaus, 179
 Ram, Sanjay, 540
 Ranasinghe, Srinika, 597
 Ravneberg, David H., 141

 Rawale, Sharad V., 472
 Reid, Kenneth B. M., 455
 Remick, Daniel G., 623
 Remmerswaal, Ester B. M., 221
 Repp, Roland, 337
 Reynolds, Joseph M., 313
 Rice, Peter A., 540
 Richter, Martin V., 201
 Robinson, Richard T., 71
 Roderiquez, Gregory, 45
 Romero, Ana I., 21
 Roosnek, Eddy, 221
 Roscher, Silke, 455
 Rothenberg, Ellen V., 421
 Rothstein, Thomas L., 229
 Rowen, Lee, 421
 Rudd, Christopher E., 400
 Ruggiero, Raúl A., 673
 Ruipérez, Violeta, 631
 Russell, Marsha S., 211
 Russo, Vincenzo, 357
 Ryan, John J., 665

 Saban, Daniel R., 382
 Sad, Subash, 211
 Sancho, Jaime, 31
 Sandau, Michelle M., 120
 Sankarshanan, Mohan, 483
 Sato, Shinichi, 698
 Sauerwein, Robert W., 162
 Schindler, Christian, 463
 Schleimer, Robert P., 578
 Schmidt-Supprian, Marc, 179
 Schwartz, Lawrence B., 665
 Schwarz, Thomas, 365
 Seman, Michel, 186
 Sen, Jyoti Misra, 126
 Serhan, Charles N., 616
 Sgroi, Dennis, 195
 Shanley, Crystal, 522
 Shaw, Michael, 514
 Shen, Dongxiao, 691
 Sheridan, Brian S., 322
 Sherman, Melanie A., 566
 Shiota, Hidekazu, 329
 Sica, Michela, 372
 Siddiqui, Javed, 623
 Singhanian, Neil, 682
 Sleckman, Barry P., 449
 Sly, Peter D., 132
 Sobel, Raymond A., 179
 Sozzani, Silvano, 673
 Spicer, S. Timothy, 172
 Steeber, Douglas A., 698
 Stockmeyer, Bernhard, 337
 Stout, Robert D., 313
 Stover, Alex, 665
 Stuhlmeier, Karl M., 655
 Sturm, Andreas, 295
 Sung, Sun-sang J., 391
 Suttles, Jill, 313
 Szigligeti, Peter, 346

 Tabata, Chiharu, 708
 Tabata, Rie, 708
 Tada, Norihiro, 639
 Tager, Andrew M., 691
 Taghon, Tom, 421
 Tailor, Prafullakumar, 26
 Takahashi, Meiko, 708
 Takaishi, Hironari, 639
 Takatsu, Kiyoshi, 284
 Takehara, Kazuhiko, 698
 Takito, Jiro, 639
 Tal-Lapidot, Guy, 41
 Tamura, Tomohiko, 26
 Tanaka, Ryoichi, 284
 Tancowny, Brian, 578

- Tangye, Stuart G., 13
Tedder, Thomas F., 698
ten Berge, Ineke J. M., 221
Terrazzano, Giuseppe, 372
Teske, Sabine, 247
Tesselaar, Kiki, 221
Thorén, Fredrik B., 21
Tobes, Raquel, 31
Topham, David J., 201
Toshchakov, Vladimir Y., 236
Toyama, Yoshiaki, 639
Tran, Giang T., 172
Traversari, Catia, 357
Troadec, Samuel, 409
Troncone, Riccardo, 372
Troudt, Jolynn, 522
Truong-Tran, Quynh Ai, 578
Tulic, Meri K., 132
Turnbull, Emma, 597
Turner, Stephen J., 64
Tydell, C. Chace, 421

Ulanova, Marina, 256
Unanue, Emil R., 5

Upham, John W., 132

van der Ven, André J. A. M., 162
Van Dyke, Thomas E., 647
van Leeuwen, Ester M. M., 221
van Lier, René A. W., 221
Vanzulli, Silvia, 673
Vepachedu, Ramarao, 682
Villablanca, Eduardo J., 357
Villoutreix, Bruno O., 540
Vogel, Stefanie N., 236
Voskort, Maik, 365
Vrisekoop, Nienke, 221
Vulcano, Marisa, 673

Wallis, Russell, 455
Wang, Hongyan, 400
Wang, Jinhai, 45
Wei, Bin, 400
Weissert, Robert, 179
Welch, Kathy, 623
Weslow-Schmidt, Janet L., 141
Wiedenmann, Bertram, 295

Winslow, Monte M., 103
Winstead, Colleen J., 120
Winstone, Nicola, 597

Xiong, Huabao, 26
Xu, Mai, 126

Yagita, Hideo, 36
Yahr, Timothy L., 505
Yamamoto, Kazuhiko, 284
Yang, Hongbing, 597
Yang, Huan, 623
Yarovinsky, Timur O., 505
Yoon, Heesik, 391
Yu, Qing, 126

Zaiss, Dietmar M., 201
Zanin-Zhorov, Alexandra, 41
Zanzi, Delia, 372
Zappacosta, Serafino, 372
Zhang, Ning, 578
Zhao, Wei, 665
Zhao, Wenli, 463
Ziegler, Kirk, 5

***The Journal of Immunology* Information for Authors**

Go to <http://www.jimmunol.org> for the most up-to-date instructions and manuscript submission forms.

Editorial Office E-mail: infoji@aai.org

Phone: 301-634-7197

Fax: 301-634-7829

ABOUT THE JOURNAL

The Journal of Immunology (*The JI*) is owned and published by The American Association of Immunologists, Inc. (AAI). It has an impact factor of 6.387, placing it 12th among all publications focused on immunology. *The JI* is cited more than any other immunology journal (112,686 citations in 2005). In 2006, *The JI* published 1,845 manuscripts in over 16,000 pages. This effort is supported by a trained publication and editorial services staff using customized software to track and deliver manuscripts for review and for final publication online and in print.

Other important facts:

Scope: Basic and clinical studies in all aspects of immunology. Circulation as of 9/15/06: 7,225.

Publication schedule: Printed and posted online twice each month. Print issues publish on the 1st and the 15th of each month.

Average time from submission to initial decision: 37 days.

Average time from acceptance to print: 7.5 weeks.

Acceptance rate in 2006: 45% for full-length papers, 23% for Cutting Edge papers.

JOURNAL SCOPE AND CONTENT

Full-Length Articles: *The JI* publishes novel peer-reviewed findings in all areas of experimental immunology. Manuscripts are published in the following sections:

Cellular Immunology and Immune Regulation

Clinical Immunology

Host Defense

Immunogenetics

Inflammation

Molecular and Structural Immunology

Major criteria for acceptance are quality, originality, clarity, and conciseness. Submission of a manuscript implies that the data have not been published previously and will not be submitted for publication elsewhere while the manuscript is under review.

Descriptions of new reagents, research techniques, or clinical case reports usually are appropriate only to the extent they provide innovative insights into unresolved problems or represent major breakthroughs.

The JI will not publish descriptive manuscripts that report the identification of epitopes recognized by B or T cells, unless such identification can be considered of unusual immunological significance. *The JI* usually will not publish the definition of peptide binding motifs for previously uncharacterized MHC products, regardless of species or method used. Similarly, *The JI* usually will not publish surveys of possible or actual epitopes from pathogens not previously examined for T cell epitopes. Authors should address the immunological significance explicitly and convincingly when submitting a paper that may fall into the above categories. Those wishing to report the identification of epitopes may do so at the Immune Epitope Database and Analysis Resource (<http://www.immunepitope.org/home/do>).

The JI will consider for publication comparative analysis of proteins of immunological interest (intra- or inter-species comparisons) only if such manuscripts transcend a simple descriptive examination and reveal aspects of significance to evolution and/or function of such proteins that are not intuitively obvious.

The JI will publish manuscripts that describe the characterization of the three-dimensional structure of antibody-defined epitopes, antigen-antibody, or peptide-MHC complexes only if such structures reveal features that are unique in an immunologically relevant manner. *The JI* usually will not publish structures of new MHC allelic products not previously crystallized, homologs from previously uncharacterized species, or peptide-MHC complexes composed of known MHC allelic products but with different peptides. Reports of the three-dimensional structures of allergens or other antigens likewise also fall under this description. The editors consider the atomic structure of antigen-antibody, MHC-peptide, and TCR-MHC complexes sufficiently well established to insist on immunological relevance as a criterion for publication in *The JI*.

Cutting Edge Articles: Cutting Edge is the rapid publication section of *The JI*, presenting short reports describing significant advances in an area of immunology. Manuscripts submitted for consideration in this section should present scientifically sound and novel research in a clear and concise fashion and contain conclusions of unusual interest to immunologists that are justified from the data presented. Chief criteria for acceptance are scientific novelty and quality, originality, clarity, and conciseness. In addition to research articles, the Cutting Edge section publishes invited brief commentaries on controversial subjects of broad interest to immunologists.

In This Issue: A small number of papers regarded by reviewers and editors as the top 10% in their field are highlighted in this section.

Letters to the Editor: The Editor-in-Chief invites brief letters (250 words or less) of general interest, commenting on work published in *The JI* within the previous three months. A limited number of letters will be selected for publication. The authors of the original work will be invited to respond, and both the original letter and the authors' response will be published together. If you are interested in commenting on a published paper, e-mail the Editor-in-Chief at eic@aai.org.

Pillars of Immunology: In the first issue of each month, *The JI* reprints papers regarded as classics in the field. An invited commentary accompanies each reprinted article. Suggestions for significant articles may be made by e-mail to the Editor-in-Chief at eic@aai.org.

Brief Reviews: *The JI* publishes a small number of invited reviews on a regular basis. These reviews are four to six journal pages in length, including illustrations and references. They cover a focused area on the advancing edge of immunology and provide a balanced view of current research that can be understood by

researchers outside of that specialty. Authors interested in submitting an article to Brief Reviews should submit a proposal, including an outline of the proposed review, by e-mail to the Editor-in-Chief at eic@aai.org.

EDITORIAL POLICIES REGARDING MANUSCRIPT SUBMISSION

Prior publication: Submission of a manuscript to *The JI* implies that the content has not been published previously and will not be submitted for publication elsewhere while the manuscript is under review. *The JI* considers research results (excluding abstracts and student dissertations) to have already been published if they are publicly available with a fixed content, i.e., content is in an unalterable form, and is citable in any language.

Previous publication of a particular figure may not prevent subsequent publication in *The JI* if that figure is essential to the submitted paper and does not constitute the major contribution. Previously published portions of a paper must be accompanied by a permission release from the copyright holder and must be cited.

Preprints, whether paper copies or noncitable postings on a publicly accessible website, are not considered publications, nor are poster presentations of work at a conference. An invited paper published in a non-peer-reviewed journal, however, would be considered a prior publication.

Submissions of previously published research, as defined by the criteria, must contain a disclosure statement; it is at the Editor-in-Chief's discretion whether or not to allow peer review of the work in these instances.

Copyright: All manuscripts are considered the property of AAI from the time of submission. Should AAI not publish the paper, AAI releases its rights therein at the time the manuscript is returned to the corresponding author. Manuscripts published in *The JI* become the sole property of, with all rights in copyright reserved to, The American Association of Immunologists, Inc. (AAI). The corresponding author, on behalf of all authors, signs a copyright transfer form. Authors of articles written as part of their official duties as employees of the U.S. government are exempt from this requirement for transfer of copyright.

NIH Manuscript Submission Request: For more information, go to About the NIH Public Access Policy (<http://www.jimmunol.org/misc/nihpolicy4a.shtml>). If the research described in the submitted manuscript has been funded in whole or in part by the U.S. National Institutes of Health (NIH), the following applies:

1. The NIH has adopted a new voluntary policy, which requests that authors of NIH-funded research submit their accepted manuscripts to the NIH PubMed Central repository.

2. **The NIH program is voluntary and authors do not have to participate.** NIH officials have given public assurances that there will be no repercussions if authors choose not to participate.

3. The AAI does not support this policy, which it views as a costly, duplicative effort by NIH that diverts federal dollars from biomedical research and threatens the integrity of the scientific record by creating multiple versions of the same article and allowing public dissemination of an unfinalized manuscript. The policy also puts authors at risk of inadvertently violating copyright agreements with the journals that publish their works. For more information on The AAI's concerns about the NIH policy, go to About the NIH Public Access Policy.

4. Despite the AAI's serious concerns about this policy, the AAI will accommodate authors who wish to submit their manuscripts to NIH, as described below. The AAI grants the undersigned corresponding author a one-time waiver permitting him or her to submit

to NIH PubMed Central this manuscript, if accepted for publication by *The JI*, provided:

- a) that the corresponding author agrees to instruct NIH to release the manuscript to the public no earlier than 12 months after final publication in *The JI*;

- b) that the corresponding author agrees that no changes or modifications will be made to the version of the manuscript that has been accepted by *The JI*; c) that this one-time waiver granted by the AAI applies solely to deposition into NIH PubMed Central and does not extend to any other repository, agency, or entity; and

- d) that the corresponding author agrees to, **and will include in the text of the abstract submitted to PMC**, the following disclaimer: "This is an author-produced version of a manuscript accepted for publication in *The Journal of Immunology (The JI)*. The American Association of Immunologists, Inc. (the AAI), publisher of *The JI*, holds the copyright to this manuscript. This manuscript has not yet been copyedited or subjected to editorial proofreading by *The JI*; hence, it may differ from the final version published in *The JI* (online and in print). The AAI (*The JI*) is not liable for errors or omissions in this author-produced version of the manuscript or in any version derived from it by the U.S. National Institutes of Health or any other third party. The final, citable version of record can be found at www.jimmunol.org."

Duplicate Publication and Scientific Fraud: In case of possible scientific misconduct, i.e., suspected fabrication or falsification of data, double publication, or plagiarism, the Editor-in-Chief will attempt to clarify the matter with each of the authors. Should that fail to resolve the situation satisfactorily, the Editor-in-Chief will contact the institution of the corresponding author. The institution should then make an inquiry and report to the Editor-in-Chief. Until the matter is clarified, no papers by any authors on the disputed manuscript will be considered for publication. If scientific misconduct is confirmed by institutional review, the Editor-in-Chief will report it to the Publications Committee. The Publications Committee, in consultation with the Council of AAI, will decide appropriate action.

Embargo Policy: For manuscripts considered to be "in press" or approved for publication, *the public release of information should not precede the actual publication of the work*. The publication date is defined as the date the first copy is mailed from the printer or the first day the issue is posted full-text online. Please note that the issue date and mail date do not necessarily coincide. This embargo policy protects the peer review process and the newsworthiness of the scientific content of published articles and minimizes the chance for the appearance of misinformation in the lay press. The policy also ensures that scientists have access to all relevant information at the same time as the public. These restrictions do not apply to the presentation of the work at scientific conferences or symposia that precede the actual publication date. Although news reporters may be present at such meetings or symposia, information, tables, or illustrations that in any way duplicate the content of a manuscript submitted for publication or "in press" should not be provided to reporters by the authors. In particular, press conferences should not be held before the embargo date. The official release of videotape presentations and electronic prepublication of articles on the Internet should adhere to the embargo policy. Violations of these policies are legitimate grounds for withdrawal of the manuscript from publication or other measures that *The JI* may choose to take.

Conflict of Interest Disclosures: Authors of submitted papers that contain information affecting actual or potential commercial products must declare any conflict of interest or financial interest in the product or in potentially competing products held by them, their spouses, or their minor children. Financial interests include

employment, consultancies, and honoraria, any of which exceed \$5,000 per year in any of the preceding five years. They also include expert testimony, royalties, grants, or patents received or pending, stock, and equity interests (diversified mutual funds or investment trusts do not constitute competing financial interests). The conflict should be stated briefly on the online manuscript submission screen, e.g., "J. B. D. has received royalty payments from PQR Incorporated." It is the responsibility of the corresponding author to review this policy with all authors and to list collectively the relevant relationships. All disclosures will remain confidential during the review process, but papers accepted for publication will acknowledge conflict of interest and financial interests in a published disclaimer describing the nature of the interests. If authors declare no conflict of interest or financial interests, this also will be noted in a published disclaimer.

Web Links in Submitted Manuscripts: Links to websites are permitted only if the information contained on the website is not essential to the understanding and assessment of the manuscript or to the ability to repeat the experiments described in the paper.

PEER REVIEW INFORMATION

The Process: By submitting a manuscript to *The JI*, the authors agree to subject it to the confidential peer-review process. Editors and reviewers are informed that the manuscript must be considered confidential. After a manuscript is received, it is assigned by the Scientific Review Coordinator to a Deputy Editor and a Section Editor, whose expertise is considered to be appropriate. The Section Editor prepares a list of expert reviewers, which may include some suggested by the Scientific Review Coordinator. Authors can indicate specific individuals whom they would like to have excluded as reviewers as well as individuals thought to be particularly appropriate, although these suggestions may not always be accepted. Generally, requests to exclude certain potential reviewers will be honored except in fields with a limited number of experts.

All potential reviewers are contacted individually to determine availability. Manuscript files are sent to at least two expert reviewers. Reviewers are asked to complete the review of the manuscript within two weeks and to return a short review form. Based on the reviewers' comments, the Section Editor recommends a course of action and communicates the reviews and recommendations to the Deputy Editor for a final decision.

The Deputy Editor considers the comments made by the reviewers and the recommendation of the Section Editor, selects those comments to be shared with the authors, makes a final decision concerning the manuscript, and prepares the decision letter for signature by the Editor-in-Chief. If revisions of the manuscript are suggested, the Deputy Editor also recommends who should review the revised paper when resubmitted. Authors are informed of the decision by e-mail; appropriate comments from reviewers and editors are appended.

Decisions: There are four categories for initial decisions: accept, accept with minor revision, return for revision, and reject. Some manuscripts are accepted provisionally, pending relatively minor revisions. In this case, the Deputy Editor may conduct the re-review. For many manuscripts, authors are invited to resubmit if revision or additional experimentation can address major criticisms. Typically, one or more reviewers will then be asked to consider the adequacy of the revisions. Cutting Edge papers are allowed only minor revisions because of time constraints. All revised manuscripts are carefully reexamined, and ultimate acceptability is not guaranteed. *The JI* does not provide for an advance determination of the acceptability of a particular manuscript for

publication, nor does it promise expedited review of selected manuscripts.

Communication with Authors: To minimize the possibility of misinterpretation or errors in verbal communication, the Editorial Office will provide information, in writing, only to the corresponding author and will not provide extensive details (e.g., exact status of a review or a predicted time to final decision). Deputy Editors do not take calls from authors concerning decisions or other related matters. All such inquiries should be addressed in writing to the Editor-in-Chief, who will discuss concerns with the Deputy Editor. This policy has been established to provide for uniformity and fairness in addressing concerns about the review process.

Rebuttals: If the authors believe that a serious scientific error occurred during the review, a letter of rebuttal may be sent to the Editor-in-Chief, explaining the reasons why the decision should be reconsidered. When appropriate, the matter will be taken up with the initial Deputy Editor, Section Editor, or additional reviewers. Rebuttals that challenge rejections that were based on priority alone are rarely successful, since the assignment of priority is necessarily a matter of opinion. If the authors of a rejected manuscript are able to make new advances that go far beyond the original submission, they will often expedite consideration of their paper through the submission of a completely new manuscript.

The JI Reviewers

Selection: Selection of reviewers is the responsibility of the Section Editor, although the Scientific Review Coordinator makes recommendations to the Section Editor from a list of individuals who have reviewed manuscripts previously. This database includes self-identified areas of expertise as well as information about the perceived usefulness and timeliness of past reviews. Individuals who consistently have provided tardy or unhelpful reviews are removed from the database. Every effort is made to avoid both real and apparent conflicts of interest with respect to research activities or collaborative or personal interactions. Reviewers are asked to withdraw from considering any manuscript in which they identify a conflict that has escaped the attention of the Section Editor.

Scientific Integrity: Information contained in manuscripts is considered confidential and should not be shared or distributed. If necessary, a reviewer can consult with others for an adequate evaluation of the research findings if all individuals involved maintain confidentiality, objectivity, and avoid conflict of interest. AAI is not responsible for acts and conduct by reviewers that are not in accordance with accepted professional standards. Reviewers are asked to be objective in their evaluations and to judge primarily the novelty and soundness of the information presented.

Anonymity: Although reviews are anonymous, all comments should be capable of withstanding public scrutiny. Except in very unusual circumstances, the identity of the reviewers and Section and Deputy Editors involved in the review of any given manuscript is kept confidential.

The JI Editorial Board: The AAI Council, upon recommendation of the Publications Committee, appoints the Editor-in-Chief for a term of five years. Deputy Editors, Section Editors, and Associate Editors are nominated by the Editor-in-Chief and appointed by the Publications Committee. Deputy Editors are appointed for variable terms. Section Editors and Associate Editors are appointed for one renewable term of two years in most circumstances. The Editor-in-Chief, the Deputy Editors, and the Section Editors constitute the Editorial Board and as such are required to be members of AAI. The Editor-in-Chief is responsible for the specific editorial conduct of *The JI*. The AAI Publications Committee is responsible for the management and evaluation of *The JI*

and any other official publications of AAI, subject to the general supervision of the AAI Council.

Manuscripts Submitted from the Institution of an Editor:

Manuscripts submitted from the institution of any Section or Deputy Editor or the Editor-in-Chief are reviewed by other editors from outside that institution. The Editorial Office ensures confidentiality and equity in reviewing all manuscripts.

ONLINE SUBMISSION

Online submission is required. Submit online at <http://jmsubmit.net>. Individual manuscript, figure, and table files must be uploaded to the system. The system then creates a single PDF for review purposes. Authors should save copies for themselves of all the files in their original formats. See the Figures section (<http://www.jimmunol.org/misc/authorfulllength.shtml#figures>) for help with preparing digital art. The JI's online submission system requires browsers where Cookies and Javascript are enabled.

After the manuscript has been checked by journal staff, the Corresponding Author will receive an e-mail acknowledging receipt of the manuscript. The e-mail contains links to the Submission Form and Color Charges Form (if applicable). The Corresponding Author must download, sign, and fax these forms to 301-634-7831 to complete the submission. The manuscript **will not be sent for review** until *The JI* Editorial Office receives these forms signed by the Corresponding Author. Please contact infoji@aai.org if you do not receive the acknowledgment e-mail. Please do NOT use the hard copy forms found in old copies of the printed journal.

PUBLICATION FEES

All publication fees are payable in U.S. dollars. Accepted manuscripts are published only upon commitment by the author(s) or institutional financial officer to pay these charges.

Submission Fee: During the submission process, Corresponding Authors who are **non-AAI members*** are required to pay \$50 by credit card (American Express, MasterCard, or Visa) for processing each submitted manuscript. If payment by credit card is impossible, please contact infoji@aai.org to arrange payment by check (drawn on a U.S. bank). Cash or purchase orders are not accepted. *There is no processing fee for regular, emeritus or honorary AAI members in good standing.

Page Charges:

- \$60 per page for up to 8 printed pages in the article.
- \$150 for each additional page from 9 to 12 pages.
- \$210 for each additional page over 12 pages.

Color Charges: Color figures may include multiple color panels. Authors will be notified of the cost of color reproduction on the Reprint Form received with their electronic page proofs and must confirm acceptance of the charges in writing. Authors should expect that color figures in the accepted paper will be reproduced in color and will incur color charges. **Note that AAI members receive a significant discount on color charges.**

- **Non-AAI Members:** \$850 for each color page, and \$300 for each additional color figure on the same color page for corresponding authors who are not AAI members (i.e., first figure on first page: \$850; second figure on the first page: \$300; first figure on second page: \$850, etc.).
- **AAI Members:** \$650 for each color page and \$300 for each additional color figure on the same page for corresponding authors who are regular, emeritus, or honorary AAI members on the date of manuscript acceptance (i.e., first figure on first page: \$650; second figure on the first page: \$300; first figure on the second page: \$650, etc.).

Online Posting Fee: \$150 per published article.

Reprints: Reprints must be ordered in advance of publication. A Reprint Form showing the cost of reprints, together with an order slip, is sent with the electronic page proofs. The invoice for reprints will also include page charges and color figure charges. Reprint orders from noncontributors must be directed to the Editorial Office. See <http://www.jimmunol.org/pdf/reprintsform07.pdf> for the Reprint Order Form.

MANUSCRIPT PREPARATION

General Guidelines: A 12-point serif font, preferably Times New Roman, is required. Do not use compressed type format. Double-space entire manuscript. The average length of full-length articles is eight printed pages. Instructions for estimating the printed length of a manuscript are included below. Each of the following components should begin on a separate page:

1. The **Title Page** must include the full title; a running title (not to exceed 60 characters); each author's full name (first name, middle initial, last name); the affiliations of all authors and their institutions, departments or organizations (use the following symbols in this order: *, †, ‡, §, ¶, ||, #, **, ††, ‡‡, §§, ¶¶, ||||, ##); and three to five keywords, selected from the Keywords list (<http://www.jimmunol.org/misc/authorfulllength.shtml#keyword>) that describe the topic of the manuscript. (Keywords are used in editor and reviewer assignments and are not published with the manuscript. Please note that the list of keywords does not represent an exhaustive view of what *The JI* considers important topics, but it has been found useful for reviewer assignment purposes.)

2. The **Abstract** must be 250 words or less for full-length manuscripts; 150 words or less for Cutting Edge. Reference citations should not be included in the *Abstract*. The species of animals or species of origin of cells used in the manuscript must be clearly stated in the Abstract.

3. The **Introduction, Materials and Methods, Results, and Discussion** sections should begin on separate pages. Do not combine the *Results* and *Discussion* sections for full-length papers.

4. If the manuscript contains human or animal studies, the *Materials and Methods* section must state that the studies have been reviewed and approved by an appropriate institutional review committee.

5. **Acknowledgments** appear immediately after the *Discussion* and before *References*.

6. **Grant support** must not be included in the *Acknowledgments* but should be cited as a footnote to the title.

7. **Disclosures** contain conflict of interest disclaimers. For more information, see the Editorial Policies Regarding Manuscript Submission.

8. **References** must be numbered as they appear in the text. All authors must be listed for each reference. If citations are included in tables or in figure legends, they must be numbered according to the position of citation of the table or figure in the text. Only published papers and papers "in press" may be included in the *References*. "In press" articles, i.e., not yet published, must be submitted as online attachments in PDF format at the time of article submission. NOTE: Do NOT submit as an attachment papers that are already published, e.g., manuscripts published ahead of print. Such papers must be incorporated into the *References* and cited with the DOI numbers and the publication dates. Citations of "manuscripts in preparation," "unpublished observations," and "personal communications" must appear parenthetically in the

text. Manuscripts "submitted for publication" (i.e., not yet accepted) also are mentioned parenthetically in the text. Written approval by the persons cited in personal communications must accompany the manuscript unless they are also authors of the manuscript submitted to *The JI*.

Format for references:

Periodicals: Wells, A. D., M. C. Walsh, D. Sankaran, and L. A. Turka. 2000. T cell effector function and anergy avoidance are quantitatively linked to cell division. *J. Immunol.* 165: 2432–2443. Books: McIntyre, T. M., and W. Strober. 1999. Gut-associated lymphoid tissue: regulation of IgA B-cell development. In *Mucosal Immunology*, 2nd ed. P. L. Ogra, J. Mestecky, E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee, eds. Academic Press, San Diego, CA. 319–356.

9. **Footnotes** should be used to designate the source of support, new or special abbreviations used, correspondence address, current address, manuscripts submitted for publication, etc. Footnotes should be numbered consecutively and will appear on the title page, but for submission are grouped together and placed on a separate page between the *References* and the *Figure Legends*.

10. **Abbreviations** that may be used without definition are provided in the Standard Abbreviations list. Spell out nonstandard abbreviations used less than three times. Nonstandard abbreviations used three or more times must be defined in a footnote. Abbreviations and their definitions must be consistent throughout the text.

11. **Figure legends** must be numbered with Arabic numerals in order of appearance in the text and should include a short title after the figure number. Where possible, symbols and patterns used to distinguish data should be defined in a key placed within the graphic rather than in the figure legend.

12. **Tables** must be numbered with Roman numerals in order of appearance in the text. Table legends are prepared as footnotes to the table and are included with the table. Tables must be in DOC file format. Each table should be submitted as a separate file.

13. **Figures** At initial submission, low-resolution figures may be submitted. At submission of a revised manuscript, high-resolution figures that meet the following specifications must be submitted.

- **Sizes:** Figures should be submitted in final size (printed 1:1). Figures may be printed in one of two formats: single-column (width from 3.37 to 8.23 cm or 20 picas) or double-column (width from 12.65 to 17.1 cm or 42 picas). The single-column format is preferred. Unless the file is too large, multi-piece figures should be submitted as a single file.
- **Text and Lines:** Text in figures should be 6–8 points in size, except for single letter markers, which may be 12 points. Helvetica should be used for all figure text (except for the use of symbols). If Helvetica is not available, Times Roman may be used. Line widths must be greater than one point thick or they will not appear on the PDF version of the article.
- **Numbering:** Figures must be numbered as they appear in the text.
- **File Format:** Figures should be in **TIFF** (better for halftone art, e.g., blots, photographs) or **EPS** (better for line art or monochrome art, i.e., anything that involves sharply delineated lines) format. While images from PowerPoint files are not usually suitable quality, as their resolution is too low for print, they may sometimes be acceptable but will result in delayed processing of the manuscript.
- **Guidelines:** For general guidelines for creating digital art, go to the Cadmus Digital Art website (<http://cjs.cadmus.com/da/guidelines.jsp>) or the Cadmus FAQ page (<http://cjs.cadmus.com/da/faq.jsp>). Topics included are:

Resolution (dots per inch)

Color requirements

Cropping and sizing

Font usage

Scanned images

Supported applications

- **Graphic Art Preflight:** To avoid production delays due to unacceptable digital art formats, authors of revised papers must check in advance whether figures meet the standards required for final print and online production. It is mandatory to use Rapid Inspector (<http://rapidinspector.cadmus.com/RapidInspector/zim/index.jsp>), a tool that walks authors through the process, to identify any potential problems that need to be corrected.

14. **Cover art** changes with each issue of *The JI*. Authors are encouraged to submit color figures with their manuscripts for possible use as cover illustrations.

15. **Estimation for printed pages:** One printed page in *The JI* contains approximately 8,000 characters, including spaces. Thus, an 8-page, full-length article would contain approximately 64,000 characters. Each line in a table occupies about 60 characters for a single-column table, and 120 characters for a double-column table. Figures occupy about 180 characters per centimeter height for single-column figures, and 360 characters for double-column figures. Determine the total character count for the text of your manuscript and add the character-equivalents for the tables and figures. This will provide a reasonable estimate for the printed length of a manuscript.

CUTTING EDGE MANUSCRIPT PREPARATION

Online submission is required. Submit online at <http://ji.msubmit.net>. Individual manuscript, figure, and table files must be uploaded to the system. The system then creates a single PDF for review purposes. Authors should save copies for themselves of all the files in their original formats. See the Figures section for help with preparing digital art. Manuscripts submitted to the Cutting Edge section should conform to the Information for Authors for full-length manuscripts presented above as well as the additional guidelines listed below:

1. List the phone number, fax number, and e-mail address of the corresponding author on the title page.
2. The *Abstract* is limited to 150 words.
3. The *Materials and Methods* section may be sharply limited but should be sufficient to allow the evaluation of results and conclusions.
4. Authors may combine the *Results* and *Discussion* sections.
5. Cutting Edge articles, including figures and references, *must fit within four journal pages*. Authors should estimate the size of figures and tables and limit the text accordingly. One printed page in *The JI* contains approximately 8,000 characters, including spaces. Thus, a 4-page Cutting Edge article would contain approximately 32,000 characters. The formula for estimating the number of pages is provided in Manuscript Preparation.

PREPARATION OF THE REVISED MANUSCRIPT

Submit the revised manuscript online at <http://ji.msubmit.net>

Follow *The JI* Editorial Office instructions contained in the previous decision letter carefully and thoroughly. A revised manuscript not returned within nine months of the date of the decision letter will be considered a new manuscript and subject to a new, complete review.

Individual manuscript, figure, and table files, and a point-by-point reply to all referee comments, must be uploaded to the system. The revised manuscript text must be marked to show changes, using highlighting or a colored font (Microsoft Word files preferred). High-resolution figure files should be submitted. Figures

must be in **TIFF** or **EPS** format; PowerPoint may be acceptable but will result in a delay in processing the submission. Instructions for figures are available at the Cadmus Digital Art website (<http://cjs.cadmus.com/da/index.jsp>). Authors should retain for themselves copies of all the files in their original formats.

After the manuscript has been checked by journal staff, the Corresponding Author will receive an e-mail acknowledging receipt of the revised manuscript. The e-mail contains links to the Submission Form and Color Charges Form (if applicable). The Corresponding Author must download, sign, and fax these forms to 301-634-7831 to complete the submission of the revised manuscript. Your manuscript **will not be sent for review** until *The JI* Editorial Office receives these forms signed by the Corresponding Author. Please contact infoji@aai.org if you do not receive the acknowledgment e-mail. Please do NOT use the hard copy forms found in old copies of the printed journal.

SUPPLEMENTAL DATA AND DEPOSITION OF MATERIALS

Supplemental Data: All supplemental material accompanying an article must be submitted with the original paper for peer review. When submitting online, upload the file when requested. Supplemental material should be limited to short videos (must be no longer than 30 seconds and under 10 MB, with no sound or voice-over) or large tables, large sequence alignments, or large data sets such as those obtained with microarray hybridization experiments. Such supplemental data must be larger than two printed journal pages; smaller pieces of data should be included in the manuscript.

Videos must be 320–480 pixels or smaller for best viewing within a browser. Submit videos in MPG or QuickTime. Change QuickTime file extensions to “.mov” so that Web browsers will recognize the file type and play the movie. Compress videos as much as possible to help control file size. Name videos by order of citation appearance (e.g., video1.mov). Authors will be notified if problems exist with videos as submitted and will be asked to take responsibility for modifications. No editing will be done to videos at the Editorial Office. Legends or short explanations of the material must accompany all supplemental material. Links to the material will appear in two places in the online journal, in the Table of Contents and in the information box associated with the first page of the full-text article. There will not be any links in the body of the article. In the printed paper, supplemental material will be footnoted the first time mentioned: “The online version of this article contains supplemental material.”

Distribution and depositing of materials:

Unique materials: It is required that unique materials described in manuscripts published in *The JI* will be made available, within reason, to qualified investigators for their own noncommercial use. A reasonable amount may be charged by authors to cover preparation and shipping of the requested material. An agreement to this effect is included in the Manuscript Submission Form.

High-resolution structural data: Any paper submitted to *The JI* that contains new high-resolution structural data requires an accession number from the Protein Data Bank (<http://www.rcsb.org/pdb/Welcome.do>) and assurance that unrestricted release will occur at or before the time of publication. The accession number should be accompanied by the website address of the databank.

Nucleotide sequences: Sequences of nucleotides or amino acids longer than 50 bases/residues should not be presented in the text or in table form, but rather should be submitted as a publication-quality figure. Original nucleotide sequences, and determined nucleotide sequences encoding reported amino acid sequences, de-

scribed in the manuscript must be submitted to GenBank or EMBL DataLibrary at the time of manuscript submission; an accession number and sequence availability are required at the time of publication. The accession number should be accompanied by the website address of the databank. Instructions on submission of data may be obtained directly from GenBank (Mail Stop K710, Los Alamos National Laboratory, Los Alamos, NM 87545) or from the European Molecular Biology Library, Nucleotide Sequence Library (Postfach 10.2209, Meyerhofstrasse 1, 6900 Heidelberg, Germany) or see NCBI's GenBank site (<http://www.ncbi.nlm.nih.gov/Genbank/index.html>).

Microarray data: *The JI* will not publish descriptive manuscripts that report microarray data, unless such information can be considered of unusual immunological significance and/or include functional experiments that provide novel insight into mechanism. As with other scientific approaches, current experimental, quantitation, verification, and statistical analyses are expected. Microarray experiments should be Minimum Information About a Microarray Experiment (MIAME) compliant (for guidelines see www.mged.org). Whereas limited online space may be available for supplemental tables associated with the manuscript, complete microarray data must be deposited in the appropriate public database; e.g., GEO (<http://www.ncbi.nlm.nih.gov/geo/>), ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>), or CIBEX (<http://cibex.nig.ac.jp/index.jsp>), and must be accessible without restriction from the date of publication. An entry name or accession number must be included in the paper before publication. The accession number should be accompanied by the website address of the databank.

STYLE GUIDE

General style conventions: In general, *The JI* follows *Scientific Style and Format*, *The CSE Style Manual for Authors, Editors, and Publishers*, seventh edition, published by the Council of Science Editors, Inc., in instances where journal style issues are not directly addressed.

Abbreviations for references: BIOSIS is the primary source for journal name abbreviations; *Index Medicus* is the secondary source.

Nomenclature: The most current links for nomenclature guidelines are posted online (<http://www.jimmunol.org/misc/authorfulllength.shtml#style>).

Allergen nomenclature: Nomenclature for allergens should be assigned in cooperation with the IUIS Allergen Sub-Committee. Authors of accepted manuscripts that describe novel allergens will be requested to complete a brief standard form available at IUIS Allergen Nomenclature (<http://www.allergen.org/>).

CD nomenclature: For the purpose of consistency, *The JI* will follow CD nomenclature. For murine molecules, *The JI* will follow the nomenclature previously published in *J. Immunol.* 160: 3861–3868, 1998. For human molecules, standard CD nomenclature will be followed as updated in *J. Immunol.* 168: 2083–2086, 2002.

Chemical names: *The JI* uses *The Merck Index* (<http://library.dialog.com/bluesheets/html/bl0304.html>) and the *IUPAC-IUB Commission on Biochemical Nomenclature-Chemical Abstracts* (<http://www.chem.qmul.ac.uk/iupac/bibliog/white.html>) as the primary references for proper spelling and style of chemical names.

Chemokine/chemokine receptor nomenclature: The systematic name for chemokines and chemokine receptors should be used. The original name may be given in parenthesis if desired. See *Cytokine* 21:48–49, 2003.

Enzyme Nomenclature: (<http://www.chem.qmul.ac.uk/iubmb/enzyme/>), is *The JI* source for style and spelling of enzyme names.

Gene nomenclature: The HUGO guidelines for gene nomenclature (<http://www.gene.ucl.ac.uk/nomenclature/>) may be used for naming human genes. Mouse Genome Informatics (http://www.informatics.jax.org/searches/marker_form.shtml) is a reference source for naming mouse genes.

Genetic nomenclature for mice: *The JI* uses the revisions for standardized genetic nomenclature for mice published periodically in *Mouse Genome*. A current listing of inbred strains of mice and rats is available at Mouse Genome Informatics. Authors are encouraged to deposit their mapping data with the Mouse Genome Database (MGD) before publication and to include the assigned MGD accession numbers in their manuscripts (http://www.informatics.jax.org/external/festing/search_form.cgi). Data may be submitted electronically by e-mail. Information about electronic submission of data sets can be obtained at the Data and Nomenclature submissions page (<http://www.informatics.jax.org/>) should be reserved with MGD in advance of publication. An electronic nomenclature submission form (<http://www.informatics.jax.org/mgihome/submissions/submit.shtml>) is available from the MGD website.

HLA nomenclature: HLA nomenclature is updated periodically by the WHO Nomenclature Committee for Factors of the HLA System. A recent reference is *Hum. Immunol.* 64: 919–920, 2003. Annual comprehensive revisions are published in *Human Immunology*, usually in the spring.

STANDARD ABBREVIATIONS

The abbreviations listed here are used without definition in articles published in *The JI*. The form may be used for both singular and plural, or made plural with “s” at the author’s option. The list of standard abbreviations is published in the first issue of each volume.

STANDARD ABBREVIATIONS

The abbreviations listed here are used without definition in articles published in *The JI*. The form may be used for both singular and plural, or made plural with “s” at the author’s option. The list of standard abbreviations is published in the first issue of each volume.

Å, angstrom
aa, amino acid (only with numbers)
Ab, antibody
ABTS, 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)
Ag, antigen
AIDS, acquired immunodeficiency syndrome
ANOVA, analysis of variance
AP-1, activator protein 1
APC, Ag-presenting cell
ATP, adenosine triphosphate (also ADP, AMP, CMP, CTP, GDP, GMP, GTP, ITP, NTP, TMP, UDP, and UTP)
AZT, 3'-azido-2'-deoxythymidine
BALT, bronchus-associated lymphoid tissue
BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid acetoxymethyl ester
BCR, B cell receptor
bp, base pair (only with numbers)
BrdU, 5-bromo-2'-deoxyuridine
BSA, bovine serum albumin
C, complement
C region, constant region of Ig
cAMP, cyclic AMP
CCL, CC chemokine ligand
CCR, CC chemokine receptor
CD40L, CD40 ligand

cDNA, complementary DNA
CDR, complementarity determining region
C/EBP, CCAAT/enhancer-binding protein
CFA, complete Freund’s adjuvant
CFSE, 5-(and 6-)-carboxyfluorescein diacetate succinimidyl ester
CFU, colony-forming unit
cGMP, guanosine 3',5'-cyclic monophosphate
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
Ci, curie
CIITA, class II transactivator
CLIP, class II-associated invariant-chain peptide
CMV, cytomegalovirus
CNS, central nervous system
CoA, coenzyme A
Con A, concanavalin A
CpG, cytosine guanine dinucleotide
cpm, counts per minute
CREB, cAMP response binding protein
cRNA, complementary RNA
CSF, colony-stimulating factor
CTL, cytotoxic T lymphocyte
CTLA, cytolytic T lymphocyte-associated Ag
CXCL, CXC chemokine ligand
CXCR, CXC chemokine receptor
d, deoxy; distilled (as in dH₂O)
D region, diversity region of Ig or T cell receptor for Ag
Da, dalton (only with numbers)
dATP, 2'-deoxyadenosine triphosphate
DEAE, diethylaminoethyl
df, degrees of freedom
DMEM, Dulbecco’s modified Eagle’s medium
DMSO, dimethylsulfoxide
DNA, deoxyribonucleic acid
DNase, deoxyribonuclease
DNP, dinitrophenyl
dNTP, 2'-deoxynucleoside 5'-triphosphate
dpm, disintegrations per minute
ds, double-stranded (as dsDNA)
DTT, dithiothreitol
E, erythrocyte
EBV, Epstein-Barr virus
EC₅₀, 50% effective concentration
ECL, enhanced chemiluminescence
ED₅₀, 50% effective dose
EDTA, ethylenediaminetetraacetic acid
EGTA, ethylene glycol-bis(β-aminoethyl ester)-*N,N,N',N'*-tetraacetic acid
ELISA, enzyme-linked immunosorbent assay
ELISPOT, enzyme-linked immunospot
EMSA, electrophoretic mobility shift assay
ERK, extracellular signal-regulated kinase
E:T ratio, effector to target ratio
Fab, Ag-binding fragment
F-actin, filamentous actin
FACS, fluorescence-activated cell sorter
FAM, 6-carboxyfluorescein
FBS, fetal bovine serum
FcR, Fc receptors (e.g., FcγRI)
FCS, fetal calf serum
FITC, fluorescein isothiocyanate
FLICE, Fas-associated death domain-like IL-1β-converting enzyme
FLIP, FLICE inhibitory protein
fMLP or FMLP, formyl-methionyl-leucyl-phenylalanine
Fura 2-AM, fura 2-acetoxymethyl ester

- g, gram (only with numbers)
 GALT, gut-associated lymphoid tissue
 GAPDH or G3PDH, glyceraldehyde-3-phosphate dehydrogenase
 G-CSF, granulocyte CSF
 GFP, green fluorescent protein
 GM-CSF, granulocyte-macrophage CSF
 gp, glycoprotein (e.g., gp100)
 GPI, glycosylphosphatidylinositol
 GST, glutathione *S*-transferase
 h, hour (only with numbers)
 H chain, heavy chain
 H&E, hematoxylin and eosin
 HBSS, Hanks' balanced salt solution
 HEPES, *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid
 HIV, human immunodeficiency virus
 HLA, human histocompatibility leukocyte Ag
 HPLC, high performance liquid chromatography
 HRP, horseradish peroxidase
 HSV, herpes simplex virus
 HUVEC, human umbilical vein endothelial cells
 IC₅₀, 50% inhibition/inhibitory concentration
 ICAM, intercellular adhesion molecule
 ICOS, inducible costimulator
 Id, idiotype; idiotypic determinant
 ID₅₀, 50% infective dose or 50% inhibiting dose
 IDO, indoleamine 2,3-dioxygenase
 IFA, incomplete Freund's adjuvant
 IFN, interferon (e.g., IFN- γ)
 Ig, immunoglobulin
 IgH, Ig heavy chain
 I κ B, inhibitory NF- κ B
 IL, interleukin (e.g., IL-2)
 i.m., intramuscular
 IMDM, Iscove's modified Dulbecco's medium
 IMEM, Iscove's minimal essential medium
 i.p., intraperitoneal
 ITAM, immunoreceptor tyrosine-based activation motif
 ITIM, immunoreceptor tyrosine-based inhibitory motif
 IU, international unit
 i.v., intravenous
 J region, joining region of Ig or T cell receptor for Ag
 JAK or Jak, Janus kinase
 JNK, c-Jun N-terminal kinase
 kb, kilobase (only with numbers)
 kbp, kilobase pair (only with numbers)
 K_a , association constant
 K_d , distribution coefficient; dissociation constant
 K_D , affinity constant
 kDa, kilodalton (only with numbers)
 L chain, light chain
 LD₅₀, 50% lethal dose
 LFA, leukocyte (lymphocyte) function-associated Ag
 LIF, leukemia inhibitory factor
 LPS, lipopolysaccharide
 LU, lytic unit
 mAb, monoclonal Ab
 MACS, magnetic-activated cell sorting
 MALDI, matrix-assisted laser desorption ionization
 MALDI-TOF, matrix-assisted laser desorption ionization-time of flight
 MALT, mucosa-associated lymphoid tissue
 MAPK, mitogen-activated protein kinase
 MCP-1, monocyte chemoattractant protein-1
 M-CSF, macrophage CSF
 2-ME, 2-mercaptoethanol
 MEK, mitogen-activated protein kinase kinase
 MEM, minimum essential medium
 MES, 2-(*N*-morpholino)ethanesulfonic acid
 mg, milligram (only with numbers)
 MHC, major histocompatibility complex
 min, minute (only with numbers)
 MIP, macrophage-inflammatory protein
 ml, milliliter (only with numbers)
 MLC, mixed lymphocyte culture
 MLR, mixed leukocyte reaction
 mo, month(s) (only with numbers)
 MOPS, 4-morpholinepropanesulfonic acid
 M_r , relative molecular mass
 mRNA, messenger RNA
 MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide
 μ g, microgram (only with numbers)
 μ l, microliter (only with numbers)
 m.w., molecular weight
 MyD88, myeloid differentiating factor 88
n, number in study or group
 NAD, nicotinamide adenine dinucleotide
 NADH, reduced NAD
 NaDodSO₄, sodium dodecyl sulfate
 NADP, NAD phosphate
 NADPH, reduced NAD phosphate
 NBT, nitroblue tetrazolium
 ND, not determined
 NDP, nucleoside 5'-diphosphate
 NF, nuclear factor
 NFAT or NF-AT, nuclear factor of activated T cells
 NF- κ B, nuclear factor κ B
 Ni-NTA, nickel-nitrilotriacetic acid
 NK cell, natural killer cell
 NMP, nucleoside 5'-monophosphate
 NO, nitric oxide
 NOD, nonobese diabetic
 NS, not significant
 nt, nucleotide (only with numbers)
 OCT, octamer-binding factor
 OD, optical density
 OVA, ovalbumin
p, probability
 PAGE, polyacrylamide gel electrophoresis
 PBL, peripheral blood lymphocyte
 PBMC, peripheral blood mononuclear cell
 PBS, phosphate-buffered saline
 PCR, polymerase chain reaction
 PE, phycoerythrin
 PECAM-1, platelet endothelial cell adhesion molecule-1
 PerCP, peridinin chlorophyll protein
 PFU, plaque-forming unit
 PG, prostaglandin
 PHA, phytohemagglutinin
 PI3K, phosphatidylinositol 3-kinase
 PIPES, piperazine-*N,N'*-bis(2-ethane sulfonic acid)
 PMA, phorbol myristate acetate
 PMSF, phenylmethylsulfonyl fluoride
 PWM, pokeweed mitogen
 r, recombinant (e.g., rIFN- γ)
 R, receptor (e.g., IL-2R)
 RACE, rapid amplification of cDNA end
 RAG, recombination-activating gene
 RANTES, regulated upon activation, normal T cell expressed and secreted
 RBC, red blood cell
 RFLP, restriction fragment length polymorphism
 RIA, radioimmunoassay
 RNA, ribonucleic acid
 RNase, ribonuclease
 rpm, revolutions per minute
 rRNA, ribosomal RNA
 RT-PCR, reverse transcriptase polymerase chain reaction
 s, second (use only with numbers)

- s.c., subcutaneous
 SCID, severe combined immunodeficiency
 SD, standard deviation
 SDS, sodium dodecyl sulfate
 SE, standard error
 SEM, standard error of the mean
 SHIP, src homology 2-containing inositol 5'-phosphatase
 SIV, simian immunodeficiency virus
 sp. act., specific activity
 SRBC, sheep red blood cells
 ss, single-stranded (e.g., ssDNA)
 SSC, standard saline citrate
 STAT, signal transducer and activator of transcription
 SV40, simian virus 40
 $t_{1/2}$, half-life, half-time
 TAMRA, 5-(and 6)-carboxytetramethylrhodamine
 TAP, transporter associated with Ag processing
 Tat, terminal deoxynucleotidyltransferase
 TBS, Tris-buffered saline
 TBST, TBS with Tween 20
 TCA, trichloroacetic acid
 TCR, T cell receptor for Ag
 TdR, thymidine deoxyribose (also UdR, AdR)
 TdT, terminal deoxynucleotidyltransferase
 TGF, transforming growth factor
 Th cell, T helper cell
 TLC, thin layer chromatography
 TLR, Toll-like receptor
 TNF, tumor necrosis factor
 TNP, trinitrophenyl
 TRAIL, TNF-related apoptosis-inducing ligand
 Tris, tris(hydroxymethyl)aminomethane
 tRNA, transfer RNA
 TUNEL, Tdt-mediated dUTP nick end labeling
 U, unit (only with numbers)
 UV, ultraviolet
 v/v, volume to volume ratio (%)
 V region, variable region of Ig
 VCAM, vascular cell adhesion molecule
 V(D)J, variable diversity joining
 VLA, very late activation Ag
 W, watt (only with numbers)
 wk, week (only with numbers)
 xid, X-linked immunodeficiency
 Zap70, ζ -associated protein 70 (or ζ -chain-associated protein 70)

Keywords

Animals

Human
 Rodent
 Other Animals

Cells

B Cells
 Dendritic Cells
 Endothelial Cells
 Eosinophils
 Mast Cells/Basophils
 Monocytes/Macrophages
 Natural Killer Cells
 Neutrophils
 Stem Cells
 Stromal Cells
 T Cells
 T Cells, Cytotoxic
 Th1/Th2 Cells

Diseases

Autoimmunity
 Diabetes
 EAE/MS

Endotoxin Shock

Graft Versus Host Disease
 Immunodeficiency Diseases
 Rheumatoid Arthritis
 Systemic Lupus Erythematosus

Infections

AIDS
 Bacterial
 Fungal
 Parasitic-Helminth
 Parasitic-Protozoan
 Viral

Molecules

AcutePhase Reactants
 Adhesion Molecules
 Antibodies
 Antigens/Peptides/Epitopes
 Autoantibodies
 Cell Surface Molecules
 Chemokines
 Complement
 Cytokine Receptors

Cytokines

Fc Receptors
 Lipid Mediators
 Lipopolysaccharide
 MHC
 Nitric Oxide
 Protein Kinases/Phosphatases
 Superantigens
 T Cell Receptors
 Transcription Factors

Processes

Allergy
 Antigen Presentation/Processing
 Apoptosis
 Cell Activation
 Cell Differentiation
 Cell Proliferation
 Cell Trafficking
 Chemotaxis
 Comparative Immunology/Evolution
 Costimulation
 Cytotoxicity
 Gene Rearrangement

Gene Regulation

Hematopoiesis
 Inflammation
 Memory
 Neuroimmunology
 Phagocytosis
 Repertoire Development
 Reproductive Immunology
 Signal Transduction
 Tolerance/Suppression/Anergy
 Transplantation
 Tumor Immunity
 Vaccination

Techniques

Gene Therapy
 Molecular Biology
 Transgenic/Knockout Mice

Tissues

Lung
 Mucosa
 Skin
 Spleen & Lymph Nodes
 Thymus

THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS

9650 ROCKVILLE PIKE • BETHESDA, MD 20814-3994

TEL: (301) 634-7195 • FAX: (301) 634-7733

FEDERAL TAX ID NO: 52-2317193

E-mail Address: members@aai.org • Website Address: <http://www.aai.org>



QUALIFICATIONS AND APPLICATION FOR REGULAR MEMBERSHIP 2007 MEMBERSHIP YEAR

The American Association of Immunologists (AAI) is a professional organization whose members have a strong interest in, and have made substantial contributions to, the science of immunology. AAI is a member of the Federation of American Societies for Experimental Biology (FASEB) and is responsible for the publication of *The Journal of Immunology*. To be eligible for election to membership in the AAI, a candidate must meet **one** of the following criteria:

1. Possess a Ph.D., (or equivalent graduate degree, e.g., D.Sc.) in immunology or related disciplines, or an M.D. (or equivalent medical degree, e.g., D.D.S.) and be the **first** author of **one** significant original publication on an immunological topic in a reputable, English language refereed journal. Manuscripts "in press" are acceptable when accompanied by a letter from the publisher or Editor-In-Chief of the journal affirming its acceptance and imminent publication. Abstracts and unpublished papers **will not** be considered in evaluating whether a candidate meets the publications requirement for membership.*
2. Be an established scientist with substantial achievement in a related discipline and have at least one collaborative paper on an immunological topic in a reputable, English language refereed journal.

** These requirements may be waived under exceptional circumstances if a candidate shows evidence of other appropriate training and/or substantial research accomplishment.*

THIS APPLICATION PACKAGE MUST INCLUDE:

1. A current copy of your curriculum vitae including bibliography.
2. A copy of the title page of a first author publication that meets the criteria.
3. The name and signature of an active AAI member as your reference.

NAME: _____
DEGREE (YEAR) & INSTITUTION: _____
PUBLICATION: _____
CURRENT TITLE/ POSITION: _____
ADDRESS: _____
STREET: _____
CITY: _____ STATE: _____ ZIP CODE: _____ COUNTRY: _____
E-MAIL ADDRESS: _____
PHONE NO: _____ FAX NO: _____
RESEARCH SPECIALTY: _____

REFERENCE:

NAME OF AAI MEMBER (please print clearly): _____
SIGNATURE OF AAI MEMBER: _____

Applications should be mailed to the AAI office and marked to the attention of the AAI Membership Department. Please **DO NOT** send payment with your application. You will be invoiced upon approval.

Application Review Deadlines:

Applications are to be received in the AAI office by the first day of each month.

2007 Dues Rates: January 1 - December 31: U.S. - \$260.00 Canadian - \$267.50 (GST incl.) International - \$260.00



THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS

9650 ROCKVILLE PIKE • BETHESDA, MD 20814-3994

TEL: (301) 634-7195 • FAX: (301) 634-7733

FEDERAL TAX ID NO: 52-2317193

E-mail Address: members@aai.org • Website Address: <http://www.aai.org>

2007 TRAINEE MEMBERSHIP APPLICATION FORM

Name: _____ E-mail Address: _____

Address: _____

City: _____ State: _____ Zip Code: _____

Phone Number: _____ Fax Number: _____

Qualified applicants must complete the information below and return this form with the required payment. Trainee members will receive a subscription to *The Journal of Immunology* and the *AAI Newsletter*. Trainee members will also have the privilege of attending and participating (without vote) in the AAI Annual Business Meeting. In addition, they will receive all AAI announcements and correspondence. Checks are to be made payable to *AAI*. All checks must be in U.S. dollars drawn on a U.S. bank and International money orders are accepted.

Individuals may remain Trainee members for a maximum of eight (8) years. Certification **must** be renewed annually.

SECTION 1 -- APPLICANT INFORMATION

☐ I am a **Pre-doctoral** Trainee -- I expect to receive the _____ (*advanced degree*) in _____ (*mo/yr*)

☐ I am a **Post-doctoral** Trainee -- I hold the following advanced degree(s) (*please indicate all advanced degrees held and the month and year conferred*): _____

SECTION 2 -- CERTIFICATION OF APPLICANT'S TRAINEE STATUS

(*to be completed by current AAI member*)

As a current member of the AAI, I hereby certify that the applicant identified above is either a regularly matriculated pre-doctoral student or a post-doctoral trainee and, as such, is eligible to remain a Trainee Member of the AAI.

Current AAI Member's Name (First, MI, Last): _____

Signature: _____

Title (Dean, Dept. Chair, or Professor in Charge): _____

AAI Member Number: _____ Date: _____

SECTION 3 -- APPLICANT PLEDGE AND PAYMENT

I _____, pledge that any print copies of *The Journal of Immunology* purchased by me at the special subscription rate to Trainee Members are for my personal use. They will not be placed in a library for general use, sold, or replace a subscription currently purchased by an institution. I also agree that my on-line access to *The JI* will not be shared with others.

JANUARY 1 - DECEMBER 31, 2007

U.S. Member

☐ \$64.00

Please select: ☐ Online ☐ Print and Online

Canadian Member

☐ \$65.86 (online subscription; GST incl.)

☐ \$165.86 (print, online, GST & airmail incl.)

International Member

☐ \$64.00 (online subscription)

☐ \$164.00 (print, online & airmail incl.)

☐ CHECK ENCLOSED

☐ VISA

☐ MASTERCARD

☐ AMERICAN EXPRESS

CARD NUMBER: _____ EXPIRATION DATE: _____

SIGNATURE: _____

EXPERIMENTAL BIOLOGY 2008

TODAY'S RESEARCH: TOMORROW'S HEALTH



April 5–April 9
San Diego Convention Center, San Diego, California



PARTICIPATING SOCIETIES

AAA

American Association of Anatomists

AAI

The American Association of Immunologists

APS

The American Physiological Society

ASBMB

American Society for Biochemistry and Molecular Biology

ASIP

American Society for Investigative Pathology

ASN

American Society for Nutrition

ASPET

American Society for Pharmacology
and Experimental Therapeutics

Experimental
Biology

2008[®]

For further information contact
eb@feseb.org or visit www.eb2008.org
EB Management Office
9650 Rockville Pike, Bethesda, MD 20814-3998
Tel: 301-634-7010 • Fax: 301-634-7014